Latest / Community Health Media
Dr. Mabel Mardones & Dr. Joyce O'Shaughnessy - T-DXd in Early HER2+ Breast Cancer
The treatment for early-stage HER2-positive breast cancer has entered a new era.
Dr. Mabel Mardones and Dr. Joyce O'Shaughnessy discuss how they are implementing trastuzumab deruxtecan (T-DXd) following the landmark DESTINY-Breast11 and DESTINY-Breast05 approvals. From patient selection and ILD monitoring to residual disease management and future treatment sequencing, this conversation explores the practical decisions clinicians are facing as T-DXd moves into curative-intent settings.
The conversation explores:
Implementing DESTINY-Breast11 in clinical practice
Which patients should receive…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.